Bee venom acupuncture, NSAIDs or combined treatment for chronic neck pain: study protocol for a randomized, assessor-blind trial by Byung-Kwan Seo et al.
TRIALS
Seo et al. Trials 2014, 15:132
http://www.trialsjournal.com/content/15/1/132STUDY PROTOCOL Open AccessBee venom acupuncture, NSAIDs or combined
treatment for chronic neck pain: study protocol
for a randomized, assessor-blind trial
Byung-Kwan Seo1, Jun-Hwan Lee2, Pil-Kun Kim1, Yong-Hyeon Baek1, Dae-Jean Jo3 and Sanghun Lee2*Abstract
Background: Chronic neck pain (CNP) is a common painful medical condition with a significant socioeconomic
impact. In spite of widespread usage, the effectiveness and safety of combined treatments between conventional
and complementary alternative medical treatment modalities has not been fully established in a rigorous
randomized clinical trial (RCT). This pilot study will provide the clinical evidence to evaluate the feasibility and refine
the protocol for a full-scale RCT on combined treatment of bee venom acupuncture (BVA) and non-steroidal
anti-inflammatory drugs (NSAIDs) in patients with CNP.
Methods/Design: This is a randomized, single-blind clinical trial with three parallel arms. Sixty patients between 18
and 65 years of age with non-specific, uncomplicated neck pain lasting for at least three months will be enrolled.
Participants will be randomly allocated into the BVA, NSAIDs or combined treatment group. Assessors and statisticians
will be blinded to the random allocation. All researchers will receive training to ensure their strict adherence to the
study protocol. Patients from the BVA and combined treatment group will be treated with a bee venom increment
protocol into predefined acupoints for six sessions over a three week period. BVA intervention is developed through a
comprehensive discussion among interdisciplinary spine disorder experts, according to the guidelines of Standards for
Reporting Interventions in Clinical Trials of Acupuncture (STRICTA). Patients from the NSAIDs and combined treatment
groups will be prescribed loxoprofen (one tablet to be taken orally, three times a day for three weeks). Bothersomeness
from CNP measured using a visual analogue scale (VAS) will be the primary outcome assessed at screening, visit two
(baseline), four, six, eight (4th week assessment) and nine (8th week assessment) follow-up session. VAS for pain
intensity, neck disability index (NDI), quality of life, depressive status and adverse experiences will also be analyzed.
Discussion: Our study results will contribute to feasibility evaluation and to relevant RCT protocol development for a
full-scale RCT on combined treatment of BVA and NSAIDs for CNP patients.
Trial registration: This study is registered with the United States (US) National Institutes of Health Clinical Trials
Registry: NCT01922466.
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Non-specific chronic neck pain (CNP) is a common
debilitating medical condition affecting 30 to 50% of
the general population and is most prevalent in mid-
dle age [1]. In Korea, the cumulative lifetime preva-
lence of CNP is 20.8% [2]. CNP causes a significant
socioeconomic impact related not only to direct med-
ical costs, but also indirect health care costs and loss
of productive capacity [1,3,4]. As a mechanical pain
without an accurately identifiable pain source [5], CNP
may be related to neck pain, upper extremity pain and
headache, but is not related to apparent radiculopa-
thies or myelopathies, including sensory and motor
dysfunction [5,6].
Depending on the tailored treatment strategies, vari-
ous treatment modalities are available for CNP in-
cluding medication (non-steroidal anti-inflammatory
drugs (NSAIDs), serotonin reuptake inhibitors and anti-
epileptics), interdisciplinary rehabilitation, physical ther-
apy, education, spinal injection and surgical interventions
[7,8]. Although pain-relieving medication is most fre-
quently used to alleviate CNP [9], longterm NSAIDs
use is limited due to the risk of side effects and pa-
tient intolerance [7].
It is reported that neck pain patients tend to concurrently
utilize both conventional treatment and complemen-
tary alternative medicine (CAM) in the hopes of more
positive effects and safety profile [10]. The use of CAM
therapeutic modalities including acupuncture, herbal
medicine, herbal acupuncture, cupping and chiroprac-
tic manipulation has been increased [11-14]. Bee venom
acupuncture (BVA) is one of the most frequently per-
formed pharmacopuncture to alleviate neck pain [15,16].
As an acupoint-stimulating treatment, BVA is utilized for
the treatment of neck pain, low back pain, acute ankle
sprain, post-stroke shoulder pain, rheumatoid arthritis,
lumbar disc herniation and osteoarthritis [16,17]. BVA has
been reported to exhibit analgesic, anti-inflammatory,
anti-arthritic and anti-cancer effects [18] in experi-
mental animal models [19,20] and in clinical studies
[15-17,21,22]. The analgesic effects of BVA are more
potent with repetitive administration than with a single
treatment [23].
Although combined treatments between conventio-
nal and CAM interventions have been frequently uti-
lized, the effectiveness and safety has not been fully
investigated in rigorously designed clinical trials. This
study may be a preliminary evaluation of the non-
inferiority of BVA against NSAIDs, and any synergis-
tic or additional effect of each. The results from this
pilot study will provide clinical evidence to evaluate
the feasibility for full-scale randomized controlled trial
(RCT) on combined treatment of BVA and NSAIDs
for CNP.Methods/Design
Trial design
This is a randomized, assessor-blind clinical trial with three
parallel arms (1:1:1 ratio) conducted at the spine center at
Kyung Hee University Hospital at Gangdong (KHUHGD).
We will compare the effects of BVA, NSAIDs and the
combined treatment of BVA and NSAIDs in patients with
CNP. The trial has been registered with the United
States (US) National Institutes of Health Clinical Trials
registry (NCT01922466) and has been approved by the
Institutional Review Board (IRB) of KHUHGD (KHNMC-
OH-IRB 2012–019). Outcome assessment and statistical
analyses will be performed by independent researchers
who are blinded to the patient assignment (Figure 1).
Participants
Sixty participants with non-specific neck pain will be re-
cruited to the study from KHUHGD through advertise-
ments in local newspapers, on hospital websites and on
bulletin boards. All participants will be interviewed by
telephone and scheduled for a screening visit by the cli-
nical research coordinator (CRC). After completing the
screening questions, participants will be guided through
the informed consent process. Participants will be in-
formed that they may be randomly allocated into any of
the three treatment groups (BVA, NSAIDs and com-
bined treatment), and that they may withdraw their
voluntary participation at any stage. Patients will be pro-
vided enough time to deliberate their participation in
the independent waiting room with the written infor-
mation and the informed consent form. As a screening
process for eligibility, a skin hypersensitivity test will be
performed on each patient at LI11 acupoints, using a
subcutaneous injection of 0.05 ml of a 1:20,000 bee ve-
nom preparation. Local swelling greater than 10 mm in
diameter or redness greater than 20 mm in diameter will
be considered a positive reaction, and these patients will
be excluded from the study. Eligible participants will be
randomly allocated into one of three parallel groups at a
ratio of 1:1:1, (BVA:NSAIDs:combined treatment). After
random allocation, the interviewer (CRC) will schedule
treatment sessions. All recruitment procedures will be
recorded in a log file.
Eligibility criteria
Patients between 18 and 65 years of age who can read
and write in Korean, who agree to participate after pro-
viding written informed consent, and who have been ex-
periencing non-specific, uncomplicated neck pain for at
least three months preceding the time of the screening
visit will be selected as study volunteers.
Patients will be excluded from the study if they have:
1) exhibited abnormalities on neurological examination
(such as cervical nerve function, deep tendon reflexes,
Figure 1 Study flowchart.
Seo et al. Trials 2014, 15:132 Page 3 of 8
http://www.trialsjournal.com/content/15/1/132voluntary muscle activation and sensory function); 2)
radicular pain; 3) serious spinal disorders including ma-
lignancy, vertebral fracture, spinal infection or inflamma-
tory spondylitis; 4) other chronic diseases that could
affect or interfere with the therapeutic outcomes includ-
ing cardiovascular disease, diabetic neuropathy, active
hepatitis, fibromyalgia, rheumatoid arthritis, dementia or
epilepsy; 5) previous spinal surgery or scheduled proce-
dures during the study; 6) a painful condition induced
by a traffic accident; 7) a substantial musculoskeletal
problem generating pain from an area other than the
neck; 8) conditions for which administration of BVA
might not be safe including clotting disorders, adminis-
tration of an anticoagulant agent, pregnancy and seizure
disorders; 9) a documented hypersensitive reaction to
previous BVA treatments, bee stings or insect bites; 10)
a positive reaction observed during a skin hypersensitiv-
ity test; 11) a severe psychiatric or psychological dis-
order; 12) current use of corticosteroids, narcotics,
muscle relaxants or herbal medicines to treat neck pain
or any medication considered inappropriate by the in-
vestigator; and 13) pending lawsuits or receipt of com-
pensation due to neck pain.
Interventions
The BVA group will be treated with a bee venom (BV)
increment protocol of six sessions over three weeks. The
NSAIDs group will be prescribed loxoprofen (loxonin,
60 mg/Tab, Dong Wha Pharm Co., Ltd, Seoul, Korea), at
a dose of one tablet administered orally three times per
day over three weeks. The combined treatment groupwill be treated according to the BV increment protocol
and will be prescribed loxoprofen over three weeks.
Bee venom acupuncture
BVA will be prepared as dried bee venom powder (Yoomil
Garden, Hwasun, Korea), diluted (1:20,000) and filtered
in normal saline (0.9% NaCl) at the Korean medical
pharmacy at KHUHGD. BVA treatment will be conducted
using 26-gauge sterile disposable syringes (Green Cross
Co., Yongin, Korea) containing bee venom diluted with
normal saline (0.9% NaCl).
After sterile skin preparation, participants will be ad-
ministered a perpendicular, subcutaneous injection at a
depth of 0.5 to 1.0 cm with the patient lying in the prone
position. The acupuncturist will treat participants under
the predefined BVA protocol at predefined acupoints.
BVA intervention will consist of six sessions twice a
week for three weeks, under the following weekly BVA
incremental protocol: 0.2 ml for the first week, 0.4 ml
for the second week and 0.8 ml for the third week. The
predefined points (SI12, SI14, BL11, BL12, TE15 and
GB21) have been carefully selected from textbooks and
research articles by a process of consensus among par-
ticipating Korean medical doctors (KMD), all of whom
are experienced in the treatment of chronic neck pain.
Allowance of concurrent treatment of patients
During the study period, all other interventions, drugs
and treatments for neck pain will be prohibited includ-
ing surgical procedures, injections, acupuncture, physical
therapy or the use of muscle relaxants, narcotics and
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neck-pain related dysfunction will be allowed. Any
change in concurrent treatment will be recorded at
every visit.
Outcomes
Assessment of neck pain-related dysfunction, pain and
quality of life will be collected five times over eight
weeks: at screening, visit two (baseline), four, six, eight
(4th week assessment) and nine (8th week assessment)
follow-up sessions. Medical history and sociodemogra-
phic characteristics, including age, gender, marital status,
residence, occupation and education level will be taken
from the screening visit. Any unpredicted, adverse
events will be recorded at each visit (Table 1).
Primary outcome measurement
bothersomeness of chronic neck pain will be evaluated
using the 10 cm visual analog scale (VAS) for CNP. Par-
ticipants will be asked to report the degree of clinical se-
verity and impact on activities of daily life experienced
within the past week on a continuous discomfort scale
of 0 to 10 (0, absence of discomfort; 10, the worst dis-
comfort imaginable) [24] at screening, visit two (base-
line), four, six, eight (4th week assessment) and nine (8th
week assessment) follow-up sessions. The primary end
point will be the VAS score at the four-week follow-up,
one week after the completion of the three-week treat-
ment session.
Secondary outcome measurements
VAS for pain intensity
Pain intensity of CNP will be assessed using a 10 cm
VAS, a fast and straightforward method for evaluating
the subjective degree of pain intensity [25]. ParticipantsTable 1 Schedule for data collection: outcome measures per v
Measures Screening Visit 2 (baseline)
Sociodemographic characteristics ○
Physical examination ○
Laboratory tests ○
VAS for bothersomenesst of CNP ○ ○
VAS for pain intensity of CNP ○ ○
Neck disability index ○
EuroQol 5-Dimension ○
Beck’s depression inventory ○
SF-36 ○
‘Skin roll’ test ○
Credibility test ○
Adverse experiences* ○
*Adverse experiences will be monitored throughout the clinical trial.
CNP: chronic neck pain; VAS: visual analogue scale.will be asked to report the degree of pain intensity using
the 10 cm VAS (0, absence of pain; 10, the worst pain
imaginable) at screening, visit two (baseline), four, six,
eight (4th week assessment) and nine (8th week assess-
ment) follow-up sessions.
The neck disability index (NDI)
Neck pain-related dysfunction will be assessed using the
validated Korean version of NDI [26] at visit two (base-
line), four, six, eight (4th week assessment) and nine (8th
week assessment) follow-up sessions. The NDI contains
10 questions about pain intensity, personal care, lifting,
reading, headaches, concentration, work, driving, sleeping
and recreation. Each question is rated using a 6-point
scale from 0 to 5 points (0, absence of problem; 5, disabled
by neck pain).
The EuroQol 5-dimension
Quality of life (QOL) for patients with CNP will be
assessed using the Korean version of the EuroQol 5-
dimension (EQ-5D) [27,28] at visit two (baseline), four,
six, eight (4th week assessment) and nine (8th week as-
sessment) follow-up sessions. The EQ-5D contains five
questions regarding mobility, personal care, daily activ-
ities, pain/discomfort and anxiety/depression. Each
question is rated on a scale from 1 to 3 points (1, better
state of health; 3, worse state of health).
Beck’s depression inventory
The depressive status for patients with CNP will be as-
sessed using the Korean version of Beck’s Depression
Inventory (BDI) [29,30] at visit two (baseline), eight
(4th week assessment) and nine (8th week assessment)
follow-up sessions. The BDI contains 21 questions aboutisits
Visit 4 Visit 6 Visit 8 (4th week
assessment)
Visit 9 (8th week
assessment)
○
○
○ ○ ○ ○
○ ○ ○ ○
○ ○ ○ ○
○ ○ ○ ○
○ ○
○ ○
○ ○
○
○ ○ ○ ○
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the score, the lower the depressive state).
SF-36
Health-related QOL for patients with CNP will be as-
sessed using the Korean version of the Medical Outcome
Study Short-form 36-Item Health Survey (SF-36) [31,32]
at visit two (baseline), eight (4th week assessment) and
nine (8th week assessment) follow-up sessions. The SF-
36 tests the correlation between health-related QOL and
related factors (sex, age, physical function and function-
ing of daily life) rated on a 5-point scale (1, best status;
5, worst status).
Credibility test
The credibility of BVA treatments will be assessed using
the credibility test [33] at visit two (baseline) and eight
(4th week assessment) follow-up sessions. Participants
will rate the credibility of the treatment by answering
four questions regarding improvement expected, recom-
mendation to others, rationality of treatment and effect-
iveness expected for other diseases on a numeric rating
scale, with 0 as not at all and 6 as maximal agreement.
‘Skin roll’ test
Painful intervertebral dysfunction will be assessed using
the ‘skin roll’ test [34,35] at visit two (baseline), eight
(4th week assessment) and nine (8th week assessment)
follow-up sessions. The ‘skin roll’ test will be analyzed by
an averaging of each of two measured values by two in-
dependent assessors: 1) the skin fold thickness measured
using a Harpenden skinfold caliper (Baty International,
Burgess Hill, United Kingdom); 2) the pain intensity elici-
ted by pressure using a baseline dolorimeter (Fabrication
Enterprises. Inc., White Plains, United States); and 3) the
subjective pain intensity scored by the VAS.
Safety
All adverse events and vital signs will be observed and
reported according to the standard operating protocol
(SOP) of the KHUHGD IRB. Liver and renal functions
of each participant will be assessed before the treatment
and one week after the end of treatment. A pregnancy
test will be performed for female participants of child-
bearing age at any time required.
Sample size
Although there are previous researches on the effect of
BVA and NSAIDs on chronic neck pain, there are insuf-
ficient data to estimate the clinical meaningful minimal
change of the combined treatment of BVA and NSAIDs.
This study is designed to provide the clinical evidence to
estimate the sample size required for a full-scale RCT.
As a pilot trial, we will recruit 60 patients into threeparallel groups (BVA, NSAIDs or combined treatment).
We will assess the impact of the interventions and the
safety of combined treatment of different interventions
on a limited number of patients.
Randomization and allocation concealment
A total of 60 participants will be randomly assigned
following simple randomization procedures, with a 1:1:1
allocation ratio. The randomization sequence will be ge-
nerated by an independent researcher using a compu-
terized, random-number generator through a Microsoft
Office Excel 2007 software package. Opaque envelopes
labeled by study patient number will be conveyed to the
interviewer (CRC). The CRC will open the sealed enve-
lopes and allocate participants into the predefined treat-
ment arms. Allocation concealment will not be broken
until the completion of the study. The random allocation
assignment will be performed only after a participant is
confirmed to be eligible and written informed consent
has been obtained. Detailed information, including the
treatment arm and randomization number from an indi-
vidual participant will be recorded in the case report
form (CRF) and randomization table.
Blinding
As assessor-blind RCT, the researcher performing the
outcome measure assessment will be blinded to each pa-
tients’ treatment allocation and will be prohibited from
taking part in any conversation about the treatment pro-
cedures. It is not possible to conceal BVA practitioners
to patient allocations. BVA practitioners will be prohib-
ited from any conversations other than those regarding
BVA treatment. NSAIDs will be prescribed by another
researcher who will be blinded to the patient allocations
and will not be allowed to take part in any conversation
regarding the patients' condition. Participants will re-
ceive their medication at the KHUHGD pharmacy. Phar-
macists will be blinded to the patient allocations and will
only be allowed to provide general information regarding
medication administration. Statistical analysis will be
performed by an independent statistician who will be
blinded to patient allocation. All researchers will under-
go training prior to participation in this study.
Education of acupuncturists
Two licensed KMDs who specialize in acupuncture and
moxibustion will be designated as the BVA treatment
practitioners and will take educational courses to ensure
their strict adherence to the study protocol and to be-
come familiar with administering study treatments. In
order to ensure consistency in the BVA treatment, the
two acupuncturists will undergo intensive and customized
training for a full understanding of the BVA increment
Seo et al. Trials 2014, 15:132 Page 6 of 8
http://www.trialsjournal.com/content/15/1/132protocol, including details such as acupuncture points and
weekly bee venom dose increments.
Withdrawal and dropout
Participation in the study will end at any stage if the
patient refuses to continue, withdraws consent, violates
inclusion or exclusion criteria or the trial protocol, or
completes less than four treatment sessions as deter-
mined by the attending KMD researchers. The trial will
be stopped if the principle investigator believes that
there are unacceptable risks of serious adverse events.
No interim analysis will be conducted.
Planned statistical analysis
The analysis will be focused on exploring the feasibility
and acceptability of protocol implementation and refining
the protocol of future RCT. The results from hypothesis
testing will be treated as preliminary and interpreted with
caution. The results of this study may provide a prelimin-
ary evaluation of any synergistic or additional effect, and
of the non-inferiority of combined treatment of BVA and
NSAIDs. All statistical analyses will be carried out using
the Statistical Package for the Social Sciences (SPSS) for
Windows version 18.0 and will be expressed by mean and
standard deviation. The level of significance will be
set at P < 0.05. For each outcome variable, an analysis
of covariance (ANCOVA) will be performed on the
data to adjust baseline characteristics. Trends over time
and time-by-treatment interactions will be explored
using a repeated-measures analysis of variance (ANOVA).
A Chi-square test or a Fisher’s exact test will be per-
formed to determine differences between groups and
adverse effects, which will be recorded and described
as a frequency and percentage. Fisher's exact test is
used when the cell whose expected value is less than
5 is equal or more than 20%.
Ethical approval and monitoring
This study has been approved by the KHUHGD IRB
(KHNMC-OH-IRB 2012–019; April 2013). Study proce-
dures and documents will be monitored by a qualified
clinical research associate (CRA) from the Korea Insti-
tute of Oriental Medicine (KIOM).
Data handling
Data obtained during the study will be confidentially
treated according to the standard operation protocol
(SOP) of the KHUHGD IRB, and will be stored in lock-
able cabinets. All data will be processed using the partic-
ipants’ numbers which will be unrelated to participants’
personal information. Data will be compiled into CRFs
and data integration will be thoroughly verified by inde-
pendent researchers. Non-obvious errors or omissions
will be put into data query forms, which will be used forthe researchers’ workshop. Data will be gathered and
summarized with respect to demographic baseline char-
acteristics, effectiveness and safety observations.Discussion
This study will be conducted in a pragmatic setting
which is considered appropriate to evaluate a combined
treatment of BVA and NSAIDs as it is used in our usual
practice [36]. According to the clinical experience, some
patients with chronic pain tend to complain of more
discomfort and disability than pain intensity itself [37].
Also, a previous study has shown that discomfort can be
a more accurate responsive pain measure than pain
intensity or other pain measures [38]. Considering the
responsiveness study and clinical relevancy, clinical chan-
ges will be evaluated using the VAS for discomfort as a
primary outcome measure.
The BVA increment protocol and the selected acu-
points have been rigorously designed and chosen by a
process of consensus among experts according to the
Standards for Reporting Interventions in Clinical Trials
of Acupuncture (STRICTA) [39]. All study procedures
will be performed by delegated researchers trained to
meet the study protocol and good clinical practice
guidelines. In order to conceal the random allocation in
this assessor-blind design, an independent assessor will
be appointed and strictly educated to comply with the
study protocol. Data will be compiled by an independ-
ent researcher, verified through a predefined database
quality control procedure and analyzed by an inde-
pendent statistician.
Although it is designed as a pilot study, every step of
clinical study implementation will be rigorously con-
ducted, monitored and supervised to ensure methodo-
logical integrity and scientific validity. The results from
this pilot study will provide clinical evidence to evaluate
feasibility and to develop a relevant RCT protocol on
the combined treatment of BVA and NSAIDs for CNP
patients. This study is designed to determine whether
combined treatment of BVA and NSAIDs is beneficial
shortly after the end of the treatment, whether a cu-
mulative effect can be expected from BVA repetition,
whether any possible clinical impact will persist, whe-
ther patients can take any synergistic advantages, and
whether patients will be satisfied with this clinical set-
ting. The findings in this study can be used to calculate ef-
fect size and analyze confounding factors for full-scale
RCTs on the combined treatment of BVA and NSAIDs
for CNP.Trial status
This study began in July 2013 after IRB approval. Trial
completion is expected by July 2014.
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